Your browser doesn't support javascript.
loading
Evolution of clinical nature, treatment and survival of locally recurrent rectal cancer: Comparative analysis of two national cross-sectional cohorts.
van Geffen, E G M; Langhout, J M A; Hazen, S J A; Sluckin, T C; van Dieren, S; Beets, G L; Beets-Tan, R G H; Borstlap, W A A; Burger, J W A; Horsthuis, K; Intven, M P W; Aalbers, A G J; Havenga, K; Marinelli, A W K S; Melenhorst, J; Nederend, J; Peulen, H M U; Rutten, H J T; Schreurs, W H; Tuynman, J B; Verhoef, C; de Wilt, J H W; Marijnen, C A M; Tanis, P J; Kusters, M.
Afiliación
  • van Geffen EGM; Department of Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Treatment and Quality of Life and Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Langhout JMA; Department of Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Hazen SJA; Department of Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Treatment and Quality of Life and Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Sluckin TC; Department of Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Treatment and Quality of Life and Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • van Dieren S; Department of Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Beets GL; GROW School of Oncology and Developmental Biology, University of Maastricht, Maastricht, the Netherlands; Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Beets-Tan RGH; GROW School of Oncology and Developmental Biology, University of Maastricht, Maastricht, the Netherlands; Department of Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Radiology, Department of Clinical Research, University of Southern Denmark, Odense University Hos
  • Borstlap WAA; Department of Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Treatment and Quality of Life and Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Burger JWA; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
  • Horsthuis K; Department of Radiology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Intven MPW; Department of Radiotherapy, Division Imaging and Oncology, University Medical Centre Utrecht, the Netherlands.
  • Aalbers AGJ; Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Havenga K; Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Marinelli AWKS; Department of Surgery, Haaglanden Medisch Centrum, Den Haag, the Netherlands.
  • Melenhorst J; GROW School of Oncology and Developmental Biology, University of Maastricht, Maastricht, the Netherlands; Department of Surgery and Colorectal Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands.
  • Nederend J; Department of Radiology, Catharina Hospital, Eindhoven, the Netherlands.
  • Peulen HMU; Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands.
  • Rutten HJT; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.
  • Schreurs WH; Department of Surgery, Nothwest Clinics, Alkmaar, the Netherlands.
  • Tuynman JB; Department of Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Treatment and Quality of Life and Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Verhoef C; Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • de Wilt JHW; Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Marijnen CAM; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Radiation Oncology, Leiden University Medical Centre, Leiden, the Netherlands.
  • Tanis PJ; Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Department of Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
  • Kusters M; Treatment and Quality of Life and Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, the Netherlands; Department of Surgery, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands. Electronic address: m.kusters@amsterdamumc.nl.
  • On Behalf Of The Dutch Snapshot Research Group; Department of Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
Eur J Cancer ; 202: 114021, 2024 May.
Article en En | MEDLINE | ID: mdl-38520925
ABSTRACT

BACKGROUND:

In the Netherlands, use of neoadjuvant radiotherapy for rectal cancer declined after guideline revision in 2014. This decline is thought to affect the clinical nature and treatability of locally recurrent rectal cancer (LRRC). Therefore, this study compared two national cross-sectional cohorts before and after the guideline revision with the aim to determine the changes in treatment and survival of LRRC patients over time.

METHODS:

Patients who underwent resection of primary rectal cancer in 2011 (n = 2094) and 2016 (n = 2855) from two nationwide cohorts with a 4-year follow up were included. Main outcomes included time to LRRC, synchronous metastases at time of LRRC diagnosis, intention of treatment and 2-year overall survival after LRRC.

RESULTS:

Use of neoadjuvant (chemo)radiotherapy for the primary tumour decreased from 88.5% to 60.0% from 2011 to 2016. The 3-year LRRC rate was not significantly different with 5.1% in 2011 (n = 114, median time to LRRC 16 months) and 6.3% in 2016 (n = 202, median time to LRRC 16 months). Synchronous metastasis rate did not significantly differ (27.2% vs 33.7%, p = 0.257). Treatment intent of the LRRC shifted towards more curative treatment (30.4% vs. 47.0%, p = 0.009). In the curatively treated group, two-year overall survival after LRRC diagnoses increased from 47.5% to 78.7% (p = 0.013).

CONCLUSION:

Primary rectal cancer patients in 2016 were treated less often with neoadjuvant (chemo)radiotherapy, while LRRC rates remained similar. Those who developed LRRC were more often candidate for curative intent treatment compared to the 2011 cohort, and survival after curative intent treatment also improved substantially.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Recto / Recurrencia Local de Neoplasia Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Recto / Recurrencia Local de Neoplasia Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Reino Unido